蜘蛛毒液衍生药物IB409 进入人类试验 治疗心脏病发作和中风 防止缺氧 A spider venom-derived drug, IB409, enters human trials to treat heart attacks and strokes by preventing oxygen-deprivation damage.

一种来自澳大利亚漏斗网蜘蛛毒液的新药IB409已进入人类临床试验第一阶段, 治疗心脏病发作和中风。 A new drug, IB409, derived from the venom of Australia’s funnel-web spider, has entered Phase 1 human clinical trials to treat heart attacks and strokes. 该药物源于蛋白质Hi1a,其目的是防止缺氧造成的组织损伤,目前任何现有药物都没有治疗这一疾病。 Developed from the protein Hi1a, the drug aims to prevent tissue damage caused by oxygen deprivation, a condition currently untreated by any existing medication. 该审判由Infensa生物科学和昆士兰大学研究人员主持,正在评估安全性、可容忍性和剂量。 The trial, led by Infensa Bioscience and University of Queensland researchers, is assessing safety, tolerability, and dosage. 这项研究由1 780万美元的赠款资助,是朝着可能进行一流治疗以挽救生命和减少残疾迈出的重要一步。 Funded by a $17.8 million grant, the study represents a major step toward a potential first-in-class therapy that could save lives and reduce disability.